Industry News

FDA Grants Accelerated Approval to Retifanlimab-dlwr for MCC

On March 22, 2023, the U.S Food and Drug Administration granted accelerated approval to retifanlimab-dlwr for adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC).

For more information read the FDA announcement and the Incyte announcement. 

Posted 3/22/2023

1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
Email Us